Study for Sample Acquisition for Patients Diagnosed with S. aureus Bacteremia

Investigator: Henry Chambers, MD
Sponsor: Genentech, Inc.

Location(s): United States


Staphylococcus aureus is a leading cause of community-acquired and hospital-acquired bacteremia. Patients with S. aureus bacteremia can develop a broad array of complications that may be difficult to recognize initially and can increase morbidity. Mortality rates of 20 to 40 percent have been described. Mortality appears to be higher with methicillin-resistant (MRSA) compared with methicillin-sensitive S. aureus (MSSA) bacteremia.

Treatment failure (ie, death within 30 days following treatment, persistent bacteremia >10 days after initiation of appropriate therapy, or recurrence of bacteremia within 60 days of discontinuing therapy) is fairly common in patients with S. aureus bacteremia, particularly with the setting of infection due to MRSA

Ths study proposes identifying potential therapeutic targets of methicillin-resistant Staphylococcus aureus through in vivo proteomic analysis